SpectRx’ Double Play: Extend SimpleChoice Line, Ink Glucose Monitor Partner
This article was originally published in The Gray Sheet
Executive Summary
SpectRx could be cash-flow neutral in 2005 if SimpleChoice diabetes management product line sales increase as expected, CFO Thomas Muller predicted during a March 31 earnings call
You may also be interested in...
SpectRx Cervical Cancer Test Trial Begins In June; Panel Review Anticipated
SpectRx expects that data from a pivotal study of its non-invasive cervical cancer detection system will undergo FDA Obstetrics & Gynecology Devices Panel scrutiny after a PMA is submitted
SpectRx Cervical Cancer Test Trial Begins In June; Panel Review Anticipated
SpectRx expects that data from a pivotal study of its non-invasive cervical cancer detection system will undergo FDA Obstetrics & Gynecology Devices Panel scrutiny after a PMA is submitted
Abbott Acquires A Future For Its Diabetes Care Business; Where’s Bayer?
Access to a development partnership with insulin infusion pump manufacturer Smiths Medical could prove a critical component of Abbott Labs' $1.2 bil. purchase of diabetes management firm TheraSense